CYDY News and Press, CytoDyn Inc From 12/22/20

CytoDyn (CYDY) announces that a treating physician has received authorization from the FDA to administer leronlimab for a COVID-19 patient under emergency IND (eIND). In recent months, leronlimab has received more than 60 eIND authorizations from the FDA.FDA’s decision will enable the ...

FDA’s decision will enable CytoDyn to respond to ongoing requests for leronlimab until Phase 3 trial data is unblinded VANCOUVER, Washington, Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage ...

Investors Are Eyeing These 5 Penny Stocks This Week Throughout the pandemic, investors have worked to find penny stocks that may add value to their portfolios. While this can be easy for seasoned investors, newcomers may need a bit of advice to get started. With the introduction of ...

CytoDyn Inc. (CYDY) announces the full enrollment of its Phase 3 registrational trial for Vyrologix™ (leronlimab-PRO 140) in severe-to-critical COVID-19.The company is also finalizing a EUA application with the Philippine FDA with patient data from CD10 and recent eINDs for severe-to-c...

CytoDyn is simultaneously finalizing an EUA application with the Philippine FDA with patient data from CD10 and recent eINDs for severe-to-critical patients VANCOUVER, Washington, Dec. 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the &#x...

VANCOUVER, Washington, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic i...

FN Media Group Presents USA News Group News Commentary Vancouver, BC – December 2, 2020 – USA News Group – Triple-negative Breast Cancer (TNBC) is a highly aggressive subtype that accounts for 15-20% of breast cancer cases and 25% of all breast...

The first patient has been enrolled in a Phase 2 clinical trial evaluating CytoDyn' (CYDY) leronlimab, for the treatment of non-alcoholic steatohepatitis ((NASH)) and/or Nonalcoholic Fatty Liver Disease ((NAFLD)).As previously reported, the Company’s preclinical study de...

Preclinical results demonstrated leronlimab effectively inhibited fatty liver development VANCOUVER, Washington, Dec. 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrol...

FinancialBuzz.com News Commentary New York, NY (11/25/2020) – As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, according to Johns Hopkins University data. Dr. Anthony Fauci, the National Institute of Allergy and Infectious Disea...